Young biotech Codagenix just secured $3 million in funding to advance its live-attenuated RSV vaccine candidate.
Affluent regions with more new moms are most likely to be spawning grounds for antivaccine tweets, a five-year study found.
Here is some other vaccine news of note for this week.
A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.
In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
After a major cancer vaccine misstep, Bavarian Nordic reported positive six-week data from an ongoing phase 2 study on its RSV vaccine candidate.
Inovio and GeneOne have started a clinical study of their MERS vaccine in South Korea, where the virus took 36 lives in a 2015 outbreak.
Johnson & Johnson and a U.S. development agency are zeroing in on pandemic flu in a novel deal focusing on vaccine and flu drug candidates.
Secretive Moderna shared a new peek into its infectious disease vaccines efforts Thursday.
A phase 3 study shows that Seqirus' MF59-adjuvanted quadrivalent flu vaccine provides better protection in those younger than two years old.